Strategic Partnerships Joint venture with Armor Protéines to produce and commercialize human and bovine lactoferrin in 2026 presents a clear channel for co-marketing, licensing, and distribution opportunities to infant nutrition and functional food players seeking cow-free or enhanced protein ingredients.

Early Product Rollout Q1 2026 recombinant bovine lactoferrin launch indicates near-term product availability for formulators and manufacturers, enabling sales outreach to dairy alternatives, infant formula producers, and specialty nutrition brands seeking high-value dairy proteins.

Funding & Growth Significant fundraising activity and government grants demonstrate investor validation and financial runway, creating opportunities to engage prospective collaborators or customers early in product development cycles, as well as potential joint grant-funded R&D programs.

Human Protein Pipeline Active development of human milk proteins such as beta-casein and lactoferrin signals a growing addressable market for advanced infant formula ingredients, enabling outreach to formulators, bottlers, and nutrition researchers seeking closer replication of human milk profiles.

Regional Expansion Australian origin with NSW government grant support and international partnerships positions All G to target Asia-Pacific and Europe markets for precision fermentation proteins, suggesting a sales plan focused on regional distributors, manufacturing partners, and regulatory-aligned customers.